We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-9.99%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$173M
AUM Growth
-$38.5M
(-18%)
Cap. Flow
-$5.29M
Cap. Flow
% of AUM
-3.06%
Top 10 Holdings %
Top 10 Hldgs %
57.59%
Holding
58
New
12
Increased
14
Reduced
11
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$7.43M |
| 2 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$6.54M |
| 3 |
Labcorp
LH
|
+$6.2M |
| 4 |
United Therapeutics
UTHR
|
+$6.1M |
| 5 |
Tenet Healthcare
THC
|
+$5.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$8.32M |
| 2 |
Merck
MRK
|
+$7.09M |
| 3 |
CVS Health
CVS
|
+$5.06M |
| 4 |
Exelixis
EXEL
|
+$4.53M |
| 5 |
Gilead Sciences
GILD
|
+$4.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.07% |
| 2 | Consumer Staples | 2.98% |
| 3 | Technology | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cigna
CI
$73.7B
| $16.6M | 9.61% |
63,000
-12,000
| -16% | -$3.09M |
|
2
Lantheus
LNTH
$6.49B
| $16.5M | 9.55% |
250,000
| – | – |
|
3
Cerus
CERS
$433M
| $10.6M | 6.12% |
2,000,000
+350,000
| +21% | +$1.75M |
|
4
Pacira BioSciences
PCRX
$1.04B
| $10.2M | 5.9% |
175,000
-30,000
| -15% | -$1.97M |
|
|
5
Tenet Healthcare
THC
$20.5B
| $8.41M | 4.87% |
160,000
+85,000
| +113% | +$5.92M |
|
|
MDRX
6
DELISTED
Veradigm Inc. Common Stock
MDRX
| $8.16M | 4.72% |
550,000
+350,000
| +175% | +$6.54M |
|
|
7
Perrigo
PRGO
$1.4B
| $8.11M | 4.69% |
+200,000
| New | +$7.43M |
|
|
8
United Therapeutics
UTHR
$25.8B
| $7.07M | 4.09% |
+30,000
| New | +$6.1M |
|
9
SI-BONE Inc
SIBN
$788M
| $7.06M | 4.09% |
535,000
+60,000
| +13% | +$999K |
|
|
10
Merck
MRK
$322B
| $6.84M | 3.96% |
75,000
-80,000
| -52% | -$7.09M |
|
11
AngioDynamics
ANGO
$611M
| $6.19M | 3.58% |
320,000
| – | – |
|
12
Phreesia
PHR
$663M
| $6.13M | 3.54% |
245,000
+70,000
| +40% | +$1.54M |
|
|
13
Labcorp
LH
$25B
| $5.86M | 3.39% |
+29,100
| New | +$6.2M |
|
14
Amgen
AMGN
$208B
| $5.84M | 3.38% |
+24,000
| New | +$5.88M |
|
15
Turning Point Brands
TPB
$1.45B
| $5.16M | 2.98% |
190,000
-10,000
| -5% | -$293K |
|
16
Bioventus
BVS
$892M
| $5.12M | 2.96% |
750,001
-75,000
| -9% | -$765K |
|
17
Sanofi
SNY
$103B
| $4.75M | 2.75% |
+95,000
| New | +$5.04M |
|
18
AtriCure
ATRC
$1.92B
| $4.09M | 2.36% |
100,000
+35,000
| +54% | +$1.66M |
|
19
Jazz Pharmaceuticals
JAZZ
$15.9B
| $3.9M | 2.26% |
25,000
-5,000
| -17% | -$770K |
|
20
Viatris
VTRS
$20.4B
| $3.67M | 2.12% |
350,000
+125,000
| +56% | +$1.37M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.6B
| $2.49M | 1.44% |
+30,000
| New | +$2.39M |
|
22
Rigel Pharmaceuticals
RIGL
$681M
| $2.26M | 1.31% |
200,000
-125,000
| -38% | -$2.51M |
|
23
ICU Medical
ICUI
$4.21B
| $2.14M | 1.24% |
+13,000
| New | +$2.5M |
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.92M | 1.11% |
200,000
-170,000
| -46% | -$2.13M |
|
25
Collegium Pharmaceutical
COLL
$1.15B
| $1.77M | 1.03% |
+100,000
| New | +$1.68M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Tamarack Advisers held 58 positions worth $173M, down 18% from $211M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Tamarack Advisers withdrew a net $5.29M in Q2 2022, closing 17 positions and reducing 11 holdings. Its most notable exit was Medtronic, an estimated $8.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Technology.
Against the trend, Tamarack Advisers opened a new position in Perrigo worth $8.11M.
- Tamarack Advisers's largest Q2 2022 buy was Perrigo: 200,000 shares worth $8.11M.
- Tamarack Advisers added most to Veradigm Inc. Common Stock in Q2 2022, an estimated $6.54M increase.
- Tamarack Advisers's biggest Q2 2022 reduction was Merck, cutting an estimated $7.09M.
- Tamarack Advisers fully exited Medtronic in Q2 2022, selling an estimated $8.32M.
- Tamarack Advisers's ten largest holdings make up 58% of its $173M portfolio in Q2 2022.
- Tamarack Advisers opened 12 new positions and closed 17 in Q2 2022.
- Tamarack Advisers's portfolio value fell 18% quarter-over-quarter to $173M.
Based on Tamarack Advisers's 13F filing for Q2 2022, filed 16 Aug 2022.